Galderma's Restylane Shaype receives first jawline approval in Mexico
Mexico is the first market worldwide to approve the product for both chin augmentation and jawline definition, with launch anticipated in H1 2027.
See the latest news and media coverage for Galderma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global dermatology-focused pharmaceutical and skincare company
galderma.comLast updated
In short: Galderma agreed to acquire ZO Skin Health for $1.5 billion as nine-month sales rose 25.1%.
Mexico is the first market worldwide to approve the product for both chin augmentation and jawline definition, with launch anticipated in H1 2027.
It is the first ready-to-use liquid neuromodulator with PEARL Technology and is expected to launch in China in H2 2027.
Net sales reach 4.765 billion USD, driven by Therapeutic Dermatology, and full-year net sales growth guidance is raised to 22.5-23.5%
The all-cash transaction values the physician-dispensed skincare brand at 1.5 billion USD and is expected to close in late 2026 or early 2027.
Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and product categories.
The Swiss dermatology specialist exceeds market expectations after the first nine months of the year. Driven by the commercial success of Nemluvio and solid development...
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. “Our strong...
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. “Our strong performance in...
Track Galderma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Galderma and other trending companies.